Profund Advisors’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.35M Buy
240,483
+179,994
+298% +$1.13M 0.04% 294
2026
Q2
$344K Buy
60,489
+5,700
+10% +$27.9K 0.01% 726
2026
Q1
$235K Buy
54,789
+18,269
+50% +$102K 0.01% 927
2025
Q4
$327K Sell
36,520
-22,470
-38% -$139K 0.01% 808
2025
Q3
$218K Buy
58,990
+11,393
+24% +$31K 0.01% 930
2025
Q2
$92.8K Buy
47,597
+7,123
+18% +$14.8K ﹤0.01% 968
2025
Q1
$71.2K Buy
40,474
+9,195
+29% +$20.9K ﹤0.01% 971
2024
Q4
$83.2K Sell
31,279
-136
-0.4% -$350 ﹤0.01% 1083
2024
Q3
$71.9K Buy
31,415
+9,695
+45% +$29.6K ﹤0.01% 1123
2024
Q2
$63.4K Buy
+21,720
New +$66.3K ﹤0.01% 1064
2023
Q1
– Sell
-12,133
Closed -$23.3K – 1139
2022
Q4
$23.3K Buy
12,133
+699
+6% +$1.41K ﹤0.01% 999
2022
Q3
$26K Buy
11,434
+1,304
+13% +$3.72K ﹤0.01% 917
2022
Q2
$33K Sell
10,130
-1,571
-13% -$6.85K ﹤0.01% 1010
2022
Q1
$62K Sell
11,701
-916
-7% -$5.15K ﹤0.01% 1337
2021
Q4
$107K Buy
+12,617
New +$116K ﹤0.01% 1339

Other funds holding NUVB

Profund Advisors's NUVB Position: Q3 2026 in Review

Profund Advisors increased its Nuvation Bio (NUVB) stake by 298% in Q3 2026, buying an estimated $1.13M and bringing the position to 240,483 shares worth $1.35M. The position accounts for 0.04% of the portfolio, ranked #294.

Profund Advisors first reported a position in NUVB in Q4 2021 and has held it in 15 quarters since. 55 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • Profund Advisors held 240,483 shares of Nuvation Bio worth $1.35M as of Q3 2026.
  • Profund Advisors bought 179,994 Nuvation Bio shares in Q3 2026, an estimated $1.13M.
  • Nuvation Bio made up 0.04% of Profund Advisors's portfolio in Q3 2026, its #294 holding.
  • Profund Advisors first reported a position in Nuvation Bio in Q4 2021 and has held it in 15 quarters since.
  • 55 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.